Terlivaz
Payments companies reported to CMS as associated with Terlivaz. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Terlivaz, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Terlivaz
These are the largest totals companies reported as associated with Terlivaz. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Stephen Pappas | Houston, TX | Gastroenterology (Internal Medicine) | $540,498.87 |
| Santiago Munoz | Toms River, NJ | Transplant Hepatology | $330,667.34 |
| Kevin Regner | Milwaukee, WI | Nephrology (Internal Medicine) | $194,697.98 |
| Jason Rothschild | Temple Terrace, FL | Nephrology (Internal Medicine) | $150,496.63 |
| Stevan Gonzalez | Fort Worth, TX | Transplant Hepatology | $143,572.26 |
| Arun Jesudian | New York, NY | Hepatology | $136,900.16 |
| Juan Carlos Velez | New Orleans, LA | Nephrology (Internal Medicine) | $134,984.09 |
| Hany Elbeshbeshy | Saint Louis, MO | Hepatology | $125,826.26 |
| Lorenzo Rossaro | Woodland, CA | Gastroenterology (Internal Medicine) | $124,023.06 |
| Tien Dong | Santa Monica, CA | Gastroenterology (Internal Medicine) | $107,996.28 |
Prescribed Terlivaz?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.